Polyclonal Rabbit AQP3 Antibody
- Known as:
- Polyclonal Rabbit AQP3 Antibody
- Catalog number:
- abx030910
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- Polyclonal Rabbit AQP3 Antibody
Related genes to: Polyclonal Rabbit AQP3 Antibody
- Gene:
- AQP3 NIH gene
- Name:
- aquaporin 3 (Gill blood group)
- Previous symbol:
- -
- Synonyms:
- GIL
- Chromosome:
- 9p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1994-07-25
- Date modifiied:
- 2019-04-23
Related products to: Polyclonal Rabbit AQP3 Antibody
Related articles to: Polyclonal Rabbit AQP3 Antibody
- Corneal organoids derived from pluripotent stem cells have emerged as powerful tools for studying corneal development, disease modeling, and regenerative medicine applications. While previous protocols have successfully generated corneal tissue structures, there remains a need for three-dimensional models that recapitulate the complex cellular architecture and diversity of native human cornea. We developed a modified spontaneous three-dimensional corneal organoid model using human embryonic stem cells (hESCs) through an adapted Self-formed Ectoderm Autonomous Multi-zone (SEAM) protocol. hESCs were cultured as spheroids in ultra-low-binding plates under normoxic conditions and differentiated over 7-8 weeks. Organoids were characterized using immunofluorescence staining for corneal-specific markers and single-cell RNA sequencing to assess cellular composition and gene expression patterns. Approximately 20% of organoids developed transparent regions characteristic of corneal tissue by day 30 of differentiation. Immunofluorescence analysis revealed spatially organized expression of corneal markers, including ZO-1 and E-cadherin in the outermost epithelial layers, P63α-positive putative limbal stem cells at the epithelial-stromal interface, vimentin-positive stromal cells in the interior, and laminin-1 deposition that suggests Bowman's membrane formation. The organoids expressed cornea-specific keratins (K3, K12, and K15) and the master regulator PAX6 in appropriate cellular compartments. Single-cell RNA sequencing identified 18 distinct cell clusters, including three corneal epithelium subclusters with differential expression of MUC16, KRT12, and ΔNp63α, two stromal populations with distinct inflammatory profiles, and a corneal endothelium cluster. Transcriptomic analysis confirmed expression of key corneal genes, including AQP3, CDH1, multiple keratins, mucins, and extracellular matrix components (HAS2, CD34, CD44, COL8A1, and KERA). This three-dimensional spheroid-based putative corneal organoid model successfully recapitulates the multilayered architecture and cellular diversity of human cornea, including stratified epithelium, putative limbal stem cells, stroma, and endothelium in spatially appropriate arrangements. The model demonstrates molecular signatures consistent with native corneal tissue and provides a valuable platform for studying corneal development, disease mechanisms, and potential therapeutic applications. Future optimization to improve organoid formation efficiency and functional maturation will enhance the utility of this system for both basic research and translational medicine. - Source: PubMed
Publication date: 2026/04/29
Blenkinsop Timothy AEriksen Anne Z - This study evaluated whether resveratrol (RESV), alone or in combination with antifreeze protein type I (AFP I), improves slow freezing cryopreservation of in vivo-derived ovine embryos. Good-quality embryos recovered non-surgically from 35 superovulated ewes were assigned to three groups: AFP (0.1 µg/mL AFP I in the freezing solution), RESV (pre-incubation for 6 h in holding medium supplemented with 1 µM RESV before cryopreservation), or RESV + AFP (combined treatment). After thawing, embryos were cultured in vitro for 48 h and assessed for several endpoints. Resveratrol exposure (RESV and RESV + AFP) reduced intracellular levels of glutathione (GSH), reactive oxygen species (ROS), and ROS/GSH ratio after incubation (P < 0.05), without affecting mitochondrial activity. After thawing, embryos in the RESV + AFP group exhibited higher mitochondrial activity than the others (P < 0.05), accompanied by increased ROS/GSH ratios compared to AFP alone (P < 0.05). After culture, redox parameters did not differ across treatments. There was no difference in survival rates or dead cell index among groups (P > 0.05), but RESV + AFP presented the highest content of intracellular lipid (P < 0.05). Finally, expression of AQP3 and PRDX1 genes was downregulated in the AFP group compared with RESV, with no difference between RESV and RESV + AFP (P > 0.05). Altogether, combining RESV with AFP I enhanced post-thaw mitochondrial activity but disrupted redox homeostasis and increased lipid accumulation, without improving embryo survival or hatching. These findings indicate that RESV combined with AFP I does not improve embryo cryotolerance, while RESV pretreatment may help reduce oxidative stress before cryopreservation. - Source: PubMed
Publication date: 2026/05/15
Guimarães Mariana P POliveira Thaís ALeal Gabriela RCupello Ana Paula SBrandão Felipe ZBatista Ribrio Ivan T PCorreia Lucas F LSouza-Fabjan Joanna M G - Zeng Ye Tang (ZYT) is used to treat constipation caused by various factors. However, the precise mechanism underlying its therapeutic effects remains unclear. - Source: PubMed
Publication date: 2026/05/14
Wu XueWan YanZhang LinaoLuo ShifangLiu FeifanBai YuanmeiLi QingTang XianjinLi TaoTang HuaZhang YanyanXie YuhuanGuo Peixin - Pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of cancer-related mortality, with poor survival due to late diagnosis and ineffective therapies. Aquaporin-3 (AQP3) and AQP5 are transmembrane proteins overexpressed in PDAC, promoting tumor progression and metastasis, representing promising therapeutic targets. Here, we investigated their involvement in PDAC spheroids' growth and morphology using two human PDAC cell lines, BxPC-3 and MiaPaca-2. Treatment with AQP3 inhibitors decreased spheroids' diameter, area, and viability and altered MiaPaca-2 spheroids' circularity, suggesting reduced growth. Similarly, silencing AQP3 or AQP5 in BxPC-3 spheroids decreased spheroids' size with a more pronounced viability reduction, indicating impaired growth and cell death. This study demonstrates, for the first time, the critical roles of AQP3 and AQP5 in PDAC spheroids' development. - Source: PubMed
Publication date: 2026/05/17
Pimpão CatarinaEngrácia Diogo MSoveral GraçaMendes Filipa - Arsenic trioxide (ATO) is both a life-saving therapy for acute promyelocytic leukemia and a systemic toxicant whose hepatic effects remain incompletely defined. This study examined how a single clinically relevant ATO dose (8 mg/kg, i.p.) acutely remodels hepatic xenobiotic-metabolizing enzymes, arsenic transporters, and pro-inflammatory mediators in male and female C57Bl/6 mice. Mice were treated with ATO or saline and livers were collected at 6 and 24 h for integrated mRNA and protein profiling of major Cytochrome P450 (CYP) families, aquaglyceroporins (), ATP-binding cassette () transporters, and cytokines (). ATO induced highly sex-, time-, and isoform-specific reprogramming. Females exhibited a wider and earlier decline in several female-predominant CYP2, CYP3, and CYP4 isoforms, including a more pronounced reduction in hepatic CYP3A, CYP4A, and CYP4F protein abundance. In contrast, males showed mainly transcriptional induction of specific genes (, , , and ), accompanied by comparatively modest decreases in overall CYP protein levels. and transporters were differentially modulated, with males displaying early, relatively monotonic upregulation of efflux systems, while females exhibited higher basal expression but more complex, biphasic regulation of both influx () and efflux pathways. These transcriptional changes paralleled a transient inflammatory response, including early induction and female-specific elevation. Collectively, these findings highlight sex-dependent modulation of hepatic ATO handling and drug metabolizing capacity, with important implications for risk assessment and individualized ATO containing regimens. - Source: PubMed
Publication date: 2026/05/08
El-Mahrouk Sara REl-Kadi Ayman O S